Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Company Deals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Fineline Cube Jul 16, 2026
Company Deals

Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics

Fineline Cube Jul 15, 2026
Company Deals

Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger

Fineline Cube Jul 15, 2026
Company Deals

Everest Medicines and JD Healthcare Forge Strategic Digital Healthcare Alliance to Accelerate Innovative Drug Access

Fineline Cube Jul 15, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma

Fineline Cube Jul 16, 2026
Company Drug

Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy

Fineline Cube Jul 16, 2026
Company Deals

Boehringer Ingelheim Partners with Broad Institute for Mental Health Treatments

Fineline Cube Nov 5, 2024

Germany-based pharmaceutical major Boehringer Ingelheim has entered into a collaboration agreement with the Stanley Center...

Company Drug

HuidaGene Receives FDA Clinical Clearance for HG202 in Neovascular AMD Treatment

Fineline Cube Nov 5, 2024

China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced receiving clinical clearance from the US Food...

Company Medical Device

NMPA Grants Marketing License to Abonisi Medical Technology’s Knee Joint Prosthesis System

Fineline Cube Nov 5, 2024

China’s National Medical Products Administration (NMPA) has issued a marketing license to Abonisi Medical Technology...

Company Drug

Isap Biotech Secures FDA IND Approval for iSAP-0909 for Bladder Cancer Imaging

Fineline Cube Nov 5, 2024

Beijing-based biotech firm Isap Biotech has announced that it has received Investigational New Drug (IND)...

Company Drug

China Grand Pharmaceutical Completes Phase III Clinical Study for Post-Cataract Surgery Treatment

Fineline Cube Nov 5, 2024

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced the successful completion...

Company Digital

111 Inc. Appoints Yang “Luke” Chen to Board of Directors Following Resignation of Dr. Lian Yong Chen

Fineline Cube Nov 5, 2024

China-based online pharmacy 111 Inc. (NASDAQ: YI) has announced the appointment of its Senior Finance...

Company Deals

Shanghai RMX Biopharma and PharmaEngine Ink Distribution Deal for Liporaxel in Taiwan

Fineline Cube Nov 4, 2024

Chinese firms Shanghai RMX Biopharma Co. Ltd., a subsidiary of Haihe Biopharma Co., Ltd., and...

Policy / Regulatory

China’s National Allied Procurement Office Launches 10th VBP Tender Round Information Filing

Fineline Cube Nov 4, 2024

The National Allied Procurement Office has released a notification initiating the information filing process for...

Policy / Regulatory

NMPA Releases 84th Batch of Reference Drugs for GQCE and First Batch Stripped of Status

Fineline Cube Nov 4, 2024

The National Medical Products Administration (NMPA) has released the 84th batch of reference drugs for...

Company Medical Device

J&J MedTech Completes Pilot Enrollment for OMNY-AF Study on Atrial Fibrillation Treatment

Fineline Cube Nov 4, 2024

US major Johnson & Johnson (J&J, NYSE: JNJ) MedTech has announced the completion of pilot...

Company Drug

Innorna Co., Ltd Receives FDA Rare Pediatric Disease Designation for mRNA Drug IN015

Fineline Cube Nov 4, 2024

Shenzhen-based Innorna Co., Ltd has announced that it has received Rare Pediatric Disease Designation (RPDD)...

Company Drug

Teva Pharmaceutical Reports Positive Phase III Results for TEV-‘749 in Schizophrenia Trial

Fineline Cube Nov 4, 2024

Israel-based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has released new positive data on social functioning...

Company Deals

Neurodawn Pharmaceutical Secures Hundreds of Millions in Series C Financing

Fineline Cube Nov 4, 2024

Nanjing-based central nervous system (CNS) drug developer, Neurodawn Pharmaceutical Co., Ltd, has announced the successful...

Company Medical Device

Suzhou Basecare Medical’s BKA210 Receives Marketing Approval in Jiangsu Province

Fineline Cube Nov 4, 2024

China-based in vitro fertilization (IVF) specialist Suzhou Basecare Medical Co., Ltd (HKG: 2170) has announced...

Company Deals

Reprogenix Secures Over RMB100 Million in Series A Financing Led by China Venture Capital

Fineline Cube Nov 4, 2024

Hangzhou-based stem cell specialist Reprogenix has announced the successful completion of a Series A financing...

Company Drug

Novo Nordisk’s Semaglutide Meets Primary Endpoints in ESSENCE Phase III Study for MASH

Fineline Cube Nov 4, 2024

Denmark-based pharmaceutical company Novo Nordisk (NYSE: NVO; CPH: Novo-B) has announced that part 1 of...

Company Drug

Jiuzhitang Co., Ltd Announces Clinical Clearance for Volagidemab in Type 1 Diabetes

Fineline Cube Nov 4, 2024

China-based traditional Chinese medicine (TCM) giant Jiuzhitang Co., Ltd (SHE: 000989) has announced that volagidemab...

Company Drug

Shenzhen Chipscreen Biosciences Receives NMPA Approval for Chiauranib Clinical Study

Fineline Cube Nov 4, 2024

China-based biopharmaceutical company Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has received approval from the...

Company Deals

Innovent Biologics Halts Subscription Agreement with Lostrancos Ventures

Fineline Cube Nov 4, 2024

China-based Innovent Biologics, Inc. (HKG: 1801) has announced the decision not to proceed with a...

Policy / Regulatory

China’s CDE Releases 88th Batch of Reference Preparations for Generic Drug Evaluation

Fineline Cube Nov 4, 2024

The Center for Drug Evaluation (CDE) in China has announced its 88th batch of reference...

Posts pagination

1 … 303 304 305 … 695

Recent updates

  • Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma
  • Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy
  • Ascletis Pharma Selects ASC30_48 FDC as First-in-Class Oral Dual GIPR/GLP-1R Agonist for Obesity
  • Fosun Pharma Secures NMPA Approval for FXR0906, Liver-Targeted siRNA Therapy for Hypertriglyceridemia
  • China Medical System Secures NMPA Approval for CMS-D017, Novel Complement Factor B Inhibitor for AMD
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma

Company Drug

Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy

Company Drug

Ascletis Pharma Selects ASC30_48 FDC as First-in-Class Oral Dual GIPR/GLP-1R Agonist for Obesity

Company Drug

Fosun Pharma Secures NMPA Approval for FXR0906, Liver-Targeted siRNA Therapy for Hypertriglyceridemia

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.